Dabrafenib
규격
1195765-45-7CAS 번호
689-166-9EC 번호
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamideIUPAC 명칭
C23H20F3N5O2S2화학식
519.6 g/mol분자량
Dabrafenib; 1195765-45-7; GSK2118436A; GSK2118436; GSK-2118436; QGP4HA4G1B; GSK-2118436A; Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-; CHEBI:75045; DTXSID20152499; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; BENZENESULFONAMIDE, N-(3-(5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMETHYLETHYL)-4-THIAZOLYL)-2-FLUOROPHENYL)-2,6-DIFLUORO-; N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2,6-DIFLUOROBENZENESULFONAMIDE; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; dabrafenibum; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzene-1-sulfonamide; RefChem:58040; DTXCID8074990; BRAF Inhibitor GSK2118436; L01XE23; 689-166-9; N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; Tafinlar; Dabrafenib (GSK2118436); N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; MFCD17215684; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; C23H20F3N5O2S2; Dabrafenib (USAN); DABRAFENIB [USAN]; UNII-QGP4HA4G1B; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; Dabrafenib (Free Base); Dabrafenib [USAN:INN]; 1195765-45-7 (free base); Dabrafenib?; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; Dabarefenib; GSK 2118436; Tafinlar; GSK 2118436A; P06; Dabrafenib (Standard); DABRAFENIB [MI]; DABRAFENIB [INN]; DABRAFENIB [VANDF]; DABRAFENIB [WHO-DD]; MLS006011052; SCHEMBL806377; GTPL6494; orb1226829; orb1307175; orb3141313; CHEMBL2028663; SCHEMBL29350038; SCHEMBL29353365; DABRAFENIB, KB-57246; BFSMGDJOXZAERB-UHFFFAOYSA-N; GLXC-90044; HMS3656D12; HMS3672G05; HMS5081L17; EX-A1320; BDBM50428286; EBC-11470; FD5028; GSK 2118436A; HY-14660R; MSK169306; NSC764134; NSC800083; AKOS024463285; AKOS032950004; CCG-264736; CS-0692; DB08912; FA65034; NSC-764134; NSC-800083; SB13355; SDCCGSBI-0654477.P001; NCGC00346716-01; NCGC00346716-02; NCGC00346716-11; NCGC00346716-14; AC-25889; AS-19634; BP-43637; DA-62632; HY-14660; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfo; SMR004702844; NS00040699; S2807; SW219503-1; T1903; D10064; AB01565833_02; Q3011604; BRD-K09951645-001-06-8; BRD-K09951645-001-08-4; BRD-K09951645-001-11-8; BRD-K09951645-066-01-2; N-(3-(5-(2-Aminopyrimidine-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-thiazol-4-yl]-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide; N-{3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl}-2,6- difluorobenzenesulfonamide; N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide동의어